Even with the limitation of Trk protein expression in muscle tissue [52] which would lead to a certain increased background uptake, overexpression of Trk fusion proteins in certain cancer types could contribute to valuable diagnostic PET information for a specific patient population to support the therapeutic decision and to select only eligible patients for a Trk inhibitor therapy. This evidence concerns the gene TPM3 and cancer.